Pfizer posts earnings beat, raises 2019 profit forecast

  • 📰 Reuters
  • ⏱ Reading Time:
  • 26 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 14%
  • Publisher: 97%

Singapore News News

Singapore Singapore Latest News,Singapore Singapore Headlines

Pfizer Inc on Tuesday beat Wall Street estimates for quarterly profit and slight...

- Pfizer Inc on Tuesday beat Wall Street estimates for quarterly profit and slightly raised its earnings forecast for the year, as the largest U.S. drugmaker reined in costs and recorded higher sales of cancer drug Ibrance and pneumonia vaccine Prevnar.

Ibrance brought in sales of $1.13 billion during the quarter, up 21.4 percent from a year earlier, just ahead of analysts’ estimates of $1.12 billion. Prevnar raked in $1.49 billion, beating the average estimate of $1.39 billion. Pfizer is under pressure as one of its biggest drugs, Lyrica, faces generic competition. The company, therefore, has been investing in cancer treatments and gene therapies, and expects to gain approval for a new heart drug, touted as a potential blockbuster, later this year.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 2. in SG
 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

So, Congress will be able to heat their swimming pools for another year . . .

GREED over People Can Just Be So Profitable!!! HAHAHAHAHA Don't Actually CURE Anything - Just Advertise Crazy Igotahavitol Wonder Pills To Cure ANYTHING - While Giving You Horendous Side Effects BrainCandy WAKE UP PEOPLE - TRY HARDER!

Singapore Singapore Latest News, Singapore Singapore Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

LIVE: Here comes Snap's Q1 2019 earnings...Snapchat parent company Snap announces its Q1 2019 earnings after markets close on Tuesday.
Source: BusinessInsider - 🏆 729. / 51 Read more »